Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $13
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.
Guggenheim analyst Debjit Chattopadhyay maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the price target from $17 to $13.
